Skip to content

Immune Responses With Reduxium

Changes in the Immune Responses With Reduxium in Healthy Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04525456
Enrollment
20
Registered
2020-08-25
Start date
2020-10-07
Completion date
2021-01-27
Last updated
2022-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Tolerance, Viral Infection

Keywords

Antibody, Immunophenotyping, Immune cells

Brief summary

Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation. There is not enough data on the mechanism associated with the action of Reduxium or the extent of the immune response increase it produces. In this study, the investigators propose treating a group of healthy volunteers with Reduxium and investigate the utility of this approach in boosting the native and adaptive immune responses that correlate with immune protection. This may form the basis for a future study employing the product in infectious disease patients.

Detailed description

With the global population increasingly exposed to pandemic crises, permanent and expedient solutions are needed at an affordable cost. Vaccination is less than ideal as the virus is prone to a mutation that renders the previous generation of vaccine less effective. Epidemic and pandemic of viruses infection has become more common and affects both developed and less developed communities. Overcrowding and poor hygiene have been cited to be the major factors in these epidemics, but the host immune system and the ability of the human system to ward off virus infection is a factor less mentioned. Nutrition is a critical determinant of immune responses and malnutrition the most common cause of immunodeficiency worldwide. Protein-energy malnutrition is associated with a significant impairment of cell-mediated immunity, phagocyte function, complement system, secretory immunoglobulin A antibody concentrations, and cytokine production. Deficiency of single nutrients also results in altered immune responses: this is observed even when the deficiency state is relatively mild. Of the micronutrients, zinc; selenium; iron; copper; vitamins A, C, E, and B6; and folic acid have important influences on immune responses. Adequate intake of vitamins B6, folate, B12, C, E, and of selenium, zinc, copper, and iron supports a T helper cell (Th)1 cytokine-mediated immune response with sufficient production of proinflammatory cytokines, which maintains an effective immune response and avoids a shift to an anti-inflammatory Th2 cell-mediated immune response and an increased risk of extracellular infections. Supplementation with these micronutrients reverses the Th2 cell-mediated immune response to a proinflammatory Th1 cytokine-regulated response with enhanced innate immunity. Reduxium, a dietary supplement that provides immune support, is a low-cost candidate to boost immune response. Reduxium is a natural compound commercialised in the USA that helps restore homeostasis and controls inflammation. As no toxins or allergens are used, but purely food grade compounds, it is classified as a dietary supplement. Its current purpose is not to treat, diagnose, prevent or cure any disease, but it has immunomodulatory properties. Reduxium is manufactured using a proprietary reactor - a biochemical cavitation mixer that allows to create a smart small molecule. The principal device belongs to the cavitation technology family and is used for the intensification of technological processes in liquid media (liquid processing, splitting of complex molecules, cold pasteurization, destruction of solid inclusions). The usage of this process technology enables compression of a set of molecules to 1/12th their original size. Its components are: Phosphoric Acid (58%), Microelement Complex (33.6%) (Zinc, Copper, Iron Pyrophosphate, Potassium, Calcium, Silica, Glycyrrhizic Acid (8.4%). The Microelement Complex is made up of a homogenized complex with special indication, pH =0.0008-0.4, waterless in the final composition.The complex molecules generated scan at the cellular level for the presence of pathogenic (bacterial, viral, fungal) etiologies by reading the characteristics of the electron proton (KNa) pump on the membrane. If these characteristics are violated, the supplement enters the cell. At the intra-cellular level, the supplement scans the cell in search of pathology; this scanning process is made on the basis of selectivity (healthy - do not touch/ill - induce apoptosis) through the mechanism of mitochondria activity. Specifically, the complex molecules start a cascade of biochemical processes (switching to mitochondria aerobic oxidation, restarting the methyl group with the epigenetic effects on DNA, apoptosis). It is unclear how and to which extent this mechanism contributes to innate immune activation following cellular damage and stress, or how it contributes to the adaptive immune response of T and B cells. The primary objective is to analyse the changes in the immune responses after two weeks of Reduxium intake.The secondary objective is to analyse the safety and tolerability of Reduxium.

Interventions

DIETARY_SUPPLEMENTReduxium

Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.

Sponsors

National University of Singapore
CollaboratorOTHER
Ogevity Therapeutics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

single-centre, one-arm, prospective study

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects of 21 - 50 years of age * Normal blood pressure (BP \<140/90 nnHg) * Normal fasting glucose (\<6mmol/L) * Subjects must stop all supplement for 1 month prior to enrolment

Exclusion criteria

* Subjects with known history of lungs or cardiovascular disease * History of previous pancreatitis * Past or current history of malignancy * Subjects with type 2 diabetes * Past or current history of peptic ulcer disease * Current pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Liver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineLDH blood tests
Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline and weeks 3, 4, 5, 6, 7 and 8 post-baselineBlood tests of T cell subsets and phenotypes utilising groups of labelled antibodies
Immune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline and weeks 3, 4, 5, 6, 7 and 8 post-baselineBlood tests of B cell subsets and phenotypes utilising groups of labelled antibodies
Innate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeBaseline and weeks 3, 4, 5, 6, 7 and 8 post-baselineBlood tests of monocytes subsets utilising groups of labelled antibodies
Innate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeBaseline and weeks 3, 4, 5, 6, 7 and 8 post-baselineBlood tests of NK cell subsets utilising groups of labelled antibodies
Renal Panel (Sodium) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineSodium blood tests
Renal Panel (Potassium) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselinePotassium blood tests
Renal Panel (Urea) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineUrea blood tests
Renal Panel (Creatinine) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineCreatinine blood tests
Liver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineAST blood tests
Liver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineALT blood tests
Liver Panel (Albumin) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineAlbumin blood tests
Liver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineALP blood tests
Liver Panel (Bilirubin) After 2 Weeks of Reduxium IntakeBaseline and week 8 post-baselineBilirubin blood tests

Secondary

MeasureTime frameDescription
Number of Adverse Events After Reduxium IntakeBaseline and weeks 3, 4, 5, 6, 7 and 8 post-baselineTo analyse the safety and tolerability of Reduxium after 2 weeks of Reduxium intake, based on number of adverse events

Countries

Singapore

Participant flow

Recruitment details

Recruitment happened between October 7, 2020 and January 27, 2021 at National University Hospital (NUH) in Singapore.

Participants by arm

ArmCount
Reduxium
The intervention consists of 1 oral drop of Reduxium (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days.
20
Total20

Baseline characteristics

CharacteristicReduxium
Age, Continuous32.4 years
STANDARD_DEVIATION 5.4
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Singapore
20 Participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Immune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake

Blood tests of B cell subsets and phenotypes utilising groups of labelled antibodies

Time frame: Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline

Population: healthy participants

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Total B cells17.44 percentage of cellsStandard Deviation 6.89
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Total B cells21.09 percentage of cellsStandard Deviation 12.68
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Total B cells18.64 percentage of cellsStandard Deviation 7.32
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Total B cells19.84 percentage of cellsStandard Deviation 10.33
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Total B cells20.70 percentage of cellsStandard Deviation 9.28
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Total B cells20.48 percentage of cellsStandard Deviation 8.92
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Total B cells22.05 percentage of cellsStandard Deviation 10.99
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Memory B cells (MBCs)7.47 percentage of cellsStandard Deviation 3.18
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Memory B cells (MBCs)7.34 percentage of cellsStandard Deviation 3.08
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Memory B cells (MBCs)7.63 percentage of cellsStandard Deviation 3.91
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Memory B cells (MBCs)7.44 percentage of cellsStandard Deviation 3.46
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Memory B cells (MBCs)7.17 percentage of cellsStandard Deviation 2.93
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Memory B cells (MBCs)7.53 percentage of cellsStandard Deviation 3.38
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Memory B cells (MBCs)7.66 percentage of cellsStandard Deviation 3.68
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Classical MBCs1.24 percentage of cellsStandard Deviation 0.78
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Classical MBCs0.96 percentage of cellsStandard Deviation 0.55
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Classical MBCs1.06 percentage of cellsStandard Deviation 0.69
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Classical MBCs1.15 percentage of cellsStandard Deviation 0.6
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Classical MBCs0.90 percentage of cellsStandard Deviation 0.48
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Classical MBCs0.91 percentage of cellsStandard Deviation 0.53
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Classical MBCs0.93 percentage of cellsStandard Deviation 0.57
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Activated MBCs6.28 percentage of cellsStandard Deviation 2.78
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Activated MBCs6.37 percentage of cellsStandard Deviation 2.79
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Activated MBCs6.59 percentage of cellsStandard Deviation 3.69
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Activated MBCs6.46 percentage of cellsStandard Deviation 3.15
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Activated MBCs6.25 percentage of cellsStandard Deviation 2.69
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Activated MBCs6.61 percentage of cellsStandard Deviation 3.09
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Activated MBCs6.71 percentage of cellsStandard Deviation 3.38
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Tissue-like MBCs1.27 percentage of cellsStandard Deviation 0.9
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Tissue-like MBCs1.01 percentage of cellsStandard Deviation 0.62
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Tissue-like MBCs1.09 percentage of cellsStandard Deviation 0.69
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Tissue-like MBCs1.04 percentage of cellsStandard Deviation 0.63
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Tissue-like MBCs0.96 percentage of cellsStandard Deviation 0.56
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Tissue-like MBCs0.95 percentage of cellsStandard Deviation 0.54
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Tissue-like MBCs0.99 percentage of cellsStandard Deviation 0.6
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Switched B cells1.58 percentage of cellsStandard Deviation 1.24
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Switched B cells1.23 percentage of cellsStandard Deviation 1.21
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Switched B cells1.39 percentage of cellsStandard Deviation 1.21
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Switched B cells1.33 percentage of cellsStandard Deviation 1.12
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Switched B cells1.17 percentage of cellsStandard Deviation 1.06
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Switched B cells1.35 percentage of cellsStandard Deviation 1.13
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Switched B cells1.75 percentage of cellsStandard Deviation 2.15
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Unswitched B cells7.96 percentage of cellsStandard Deviation 3.37
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Unswitched B cells7.76 percentage of cellsStandard Deviation 3.26
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Unswitched B cells8.16 percentage of cellsStandard Deviation 4.27
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Unswitched B cells7.90 percentage of cellsStandard Deviation 3.6
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Unswitched B cells7.58 percentage of cellsStandard Deviation 3.07
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Unswitched B cells7.98 percentage of cellsStandard Deviation 3.52
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Unswitched B cells8.11 percentage of cellsStandard Deviation 3.83
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Naïve B cells4.74 percentage of cellsStandard Deviation 2.61
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Naïve B cells5.13 percentage of cellsStandard Deviation 3
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Naïve B cells5.02 percentage of cellsStandard Deviation 3.02
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Naïve B cells4.85 percentage of cellsStandard Deviation 3.07
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Naïve B cells4.97 percentage of cellsStandard Deviation 3.1
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Naïve B cells5.28 percentage of cellsStandard Deviation 3.18
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Naïve B cells5.55 percentage of cellsStandard Deviation 3.41
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Plasmablasts5.38 percentage of cellsStandard Deviation 3.63
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Plasmablasts4.67 percentage of cellsStandard Deviation 3.79
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Plasmablasts4.85 percentage of cellsStandard Deviation 3.68
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Plasmablasts5.12 percentage of cellsStandard Deviation 3.89
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Plasmablasts4.66 percentage of cellsStandard Deviation 3.53
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Plasmablasts4.21 percentage of cellsStandard Deviation 3.08
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Plasmablasts4.33 percentage of cellsStandard Deviation 3.26
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Exhausted B cells3.13 percentage of cellsStandard Deviation 1.83
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Exhausted B cells2.36 percentage of cellsStandard Deviation 1.48
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Exhausted B cells2.68 percentage of cellsStandard Deviation 1.88
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Exhausted B cells2.71 percentage of cellsStandard Deviation 1.5
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Exhausted B cells2.25 percentage of cellsStandard Deviation 1.22
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Exhausted B cells2.45 percentage of cellsStandard Deviation 1.33
ReduxiumImmune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Exhausted B cells2.83 percentage of cellsStandard Deviation 2.31
Primary

Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake

Blood tests of T cell subsets and phenotypes utilising groups of labelled antibodies

Time frame: Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Th1 cells47.80 percentage of cellsStandard Deviation 33.09
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Th1 cells47.30 percentage of cellsStandard Deviation 30.82
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Th1 cells47.58 percentage of cellsStandard Deviation 32.12
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Th17 cells1.28 percentage of cellsStandard Deviation 0.8
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Th17 cells1.16 percentage of cellsStandard Deviation 0.91
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Th17 cells1.21 percentage of cellsStandard Deviation 0.99
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Th17 cells1.19 percentage of cellsStandard Deviation 1.07
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Th17 cells1.16 percentage of cellsStandard Deviation 1.16
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Th17 cells1.14 percentage of cellsStandard Deviation 0.84
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Th17 cells1.24 percentage of cellsStandard Deviation 1.22
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Th2 cells2.86 percentage of cellsStandard Deviation 1.75
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Total CD8+ T cells35.08 percentage of cellsStandard Deviation 9.19
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Total CD8+ T cells34.46 percentage of cellsStandard Deviation 9.34
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Total CD8+ T cells35.30 percentage of cellsStandard Deviation 8.88
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Total CD8+ T cells34.68 percentage of cellsStandard Deviation 9.93
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Total CD8+ T cells34.49 percentage of cellsStandard Deviation 9.56
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Exhausted CD8+ T cells1.81 percentage of cellsStandard Deviation 1.15
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Exhausted CD8+ T cells2.06 percentage of cellsStandard Deviation 1.42
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Exhausted CD8+ T cells2.03 percentage of cellsStandard Deviation 1.44
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Exhausted CD8+ T cells1.61 percentage of cellsStandard Deviation 1
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Exhausted CD8+ T cells1.78 percentage of cellsStandard Deviation 1.18
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Exhausted CD8+ T cells2.00 percentage of cellsStandard Deviation 1.36
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Exhausted CD8+ T cells1.88 percentage of cellsStandard Deviation 1.08
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Total CD4+ cells54.16 percentage of cellsStandard Deviation 10.98
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Total CD4+ cells53.57 percentage of cellsStandard Deviation 12.13
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Total CD4+ cells53.97 percentage of cellsStandard Deviation 11.34
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Total CD4+ cells53.34 percentage of cellsStandard Deviation 12.22
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Total CD4+ cells53.58 percentage of cellsStandard Deviation 10.85
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Total CD4+ cells54.79 percentage of cellsStandard Deviation 12.3
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Total CD4+ cells54.49 percentage of cellsStandard Deviation 12.54
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Exhausted CD4+ T cells11.30 percentage of cellsStandard Deviation 5.46
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 -Exhausted CD4+ T cells11.93 percentage of cellsStandard Deviation 5.39
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 -Exhausted CD4+ T cells11.15 percentage of cellsStandard Deviation 4.49
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 -Exhausted CD4+ T cells10.87 percentage of cellsStandard Deviation 5.96
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 -Exhausted CD4+ T cells10.65 percentage of cellsStandard Deviation 5.15
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 -Exhausted CD4+ T cells11.59 percentage of cellsStandard Deviation 5.76
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 -Exhausted CD4+ T cells11.27 percentage of cellsStandard Deviation 4.9
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline -Regulatory T cells (Tregs)6.32 percentage of cellsStandard Deviation 1.39
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Regulatory T cells (Tregs)6.95 percentage of cellsStandard Deviation 1.5
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Regulatory T cells (Tregs)7.34 percentage of cellsStandard Deviation 1.8
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Regulatory T cells (Tregs)6.49 percentage of cellsStandard Deviation 1.93
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Regulatory T cells (Tregs)6.88 percentage of cellsStandard Deviation 1.9
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Regulatory T cells (Tregs)6.81 percentage of cellsStandard Deviation 1.9
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Regulatory T cells (Tregs)7.05 percentage of cellsStandard Deviation 1.53
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - chemokine receptor 3 (CXCR3)-Chemokine receptor 6 (CCR6)+1.02 percentage of cellsStandard Deviation 1.45
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - CXCR3-CCR6+1.24 percentage of cellsStandard Deviation 2.24
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - CXCR3-CCR6+1.09 percentage of cellsStandard Deviation 1.81
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - CXCR3-CCR6+1.60 percentage of cellsStandard Deviation 2.23
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - CXCR3-CCR6+1.34 percentage of cellsStandard Deviation 1.94
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - CXCR3-CCR6+1.32 percentage of cellsStandard Deviation 1.92
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - CXCR3-CCR6+1.09 percentage of cellsStandard Deviation 1.63
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - T helper (Th) 1/Th17 cells7.17 percentage of cellsStandard Deviation 5.19
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Th1/Th17 cells6.02 percentage of cellsStandard Deviation 5.48
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Th1/Th17 cells5.33 percentage of cellsStandard Deviation 5.12
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Th1/Th17 cells4.55 percentage of cellsStandard Deviation 3.92
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Th1/Th17 cells4.57 percentage of cellsStandard Deviation 3.67
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Th1/Th17 cells4.70 percentage of cellsStandard Deviation 3.69
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Th1/Th17 cells4.56 percentage of cellsStandard Deviation 3.8
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Th1 cells48.63 percentage of cellsStandard Deviation 24.93
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Th1 cells45.58 percentage of cellsStandard Deviation 30.23
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Th1 cells44.85 percentage of cellsStandard Deviation 31.63
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Th1 cells44.15 percentage of cellsStandard Deviation 31.98
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Th2 cells3.67 percentage of cellsStandard Deviation 2.28
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Th2 cells3.58 percentage of cellsStandard Deviation 2.13
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Th2 cells3.46 percentage of cellsStandard Deviation 1.97
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Th2 cells3.56 percentage of cellsStandard Deviation 1.94
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Th2 cells3.82 percentage of cellsStandard Deviation 2.33
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Th2 cells4.05 percentage of cellsStandard Deviation 2.23
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - T follicular helper cells (Tfh)13.75 percentage of cellsStandard Deviation 2.67
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - T follicular helper cells (Tfh)12.75 percentage of cellsStandard Deviation 3.52
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - T follicular helper cells (Tfh)12.02 percentage of cellsStandard Deviation 3.48
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - T follicular helper cells (Tfh)12.40 percentage of cellsStandard Deviation 3.83
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - T follicular helper cells (Tfh)12.22 percentage of cellsStandard Deviation 3.16
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - T follicular helper cells (Tfh)12.33 percentage of cellsStandard Deviation 3.5
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - T follicular helper cells (Tfh)11.58 percentage of cellsStandard Deviation 4.92
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Activated Tfh (Inducible T-cell Costimulator (ICOS+))0.50 percentage of cellsStandard Deviation 0.24
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Activated Tfh (ICOS+)0.45 percentage of cellsStandard Deviation 0.24
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Activated Tfh (ICOS+)0.44 percentage of cellsStandard Deviation 0.27
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Activated Tfh (ICOS+)0.38 percentage of cellsStandard Deviation 0.22
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Activated Tfh (ICOS+)0.40 percentage of cellsStandard Deviation 0.23
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Activated Tfh (ICOS+)0.47 percentage of cellsStandard Deviation 0.26
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Activated Tfh (ICOS+)0.48 percentage of cellsStandard Deviation 0.32
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Activated Tfh (Programmed cell death protein 1 (PD-1+))2.30 percentage of cellsStandard Deviation 0.84
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Activated Tfh (PD-1+)2.25 percentage of cellsStandard Deviation 0.88
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Activated Tfh (PD-1+)2.08 percentage of cellsStandard Deviation 1.01
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Activated Tfh (PD-1+)2.01 percentage of cellsStandard Deviation 0.85
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Activated Tfh (PD-1+)2.08 percentage of cellsStandard Deviation 0.85
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Activated Tfh (PD-1+)2.20 percentage of cellsStandard Deviation 0.91
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Activated Tfh (PD-1+)2.18 percentage of cellsStandard Deviation 1.16
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Activated Tfh (ICOS+PD-1+)1.18 percentage of cellsStandard Deviation 0.67
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Activated Tfh (ICOS+PD-1+)1.17 percentage of cellsStandard Deviation 0.58
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Activated Tfh (ICOS+PD-1+)1.18 percentage of cellsStandard Deviation 0.6
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Activated Tfh (ICOS+PD-1+)1.00 percentage of cellsStandard Deviation 0.49
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Activated Tfh (ICOS+PD-1+)1.08 percentage of cellsStandard Deviation 0.46
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Activated Tfh (ICOS+PD-1+)1.32 percentage of cellsStandard Deviation 0.89
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Activated Tfh (ICOS+PD-1+)1.33 percentage of cellsStandard Deviation 0.84
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Total T cells60.53 percentage of cellsStandard Deviation 9.24
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Total T cells60 percentage of cellsStandard Deviation 10.27
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 4 - Total T cells59.29 percentage of cellsStandard Deviation 9.44
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 5 - Total T cells56.52 percentage of cellsStandard Deviation 11.88
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 6 - Total T cells57.44 percentage of cellsStandard Deviation 12.75
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 7 - Total T cells58.54 percentage of cellsStandard Deviation 10.23
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 8 - Total T cells58.54 percentage of cellsStandard Deviation 11.09
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeBaseline - Total CD8 (cluster of differentiation 8)+ T cells34.08 percentage of cellsStandard Deviation 8.98
ReduxiumImmune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium IntakeWeek 3 - Total CD8+ T cells35.08 percentage of cellsStandard Deviation 8.71
Primary

Innate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium Intake

Blood tests of monocytes subsets utilising groups of labelled antibodies

Time frame: Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 8 - Intermediate monocytes7.49 percentage of cellsStandard Deviation 7.31
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeBaseline - Non-classical monocytes4.88 percentage of cellsStandard Deviation 3.41
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 3 - Non-classical monocytes2.50 percentage of cellsStandard Deviation 1.84
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 4 - Non-classical monocytes2.99 percentage of cellsStandard Deviation 2.01
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 5 - Non-classical monocytes2.94 percentage of cellsStandard Deviation 2.15
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 6 - Non-classical monocytes2.51 percentage of cellsStandard Deviation 2.04
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 7 - Non-classical monocytes2.73 percentage of cellsStandard Deviation 1.8
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 8 - Non-classical monocytes3.26 percentage of cellsStandard Deviation 1.68
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeBaseline - Intermediate monocytes7.26 percentage of cellsStandard Deviation 7.17
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 3 - Intermediate monocytes4.00 percentage of cellsStandard Deviation 5.63
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 4 - Intermediate monocytes5.60 percentage of cellsStandard Deviation 5.6
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 5 - Intermediate monocytes5.79 percentage of cellsStandard Deviation 7.2
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 6 - Intermediate monocytes5.41 percentage of cellsStandard Deviation 6.23
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 7 - Intermediate monocytes6.08 percentage of cellsStandard Deviation 6.32
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeBaseline - Classical monocytes78.92 percentage of cellsStandard Deviation 11.78
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 3 - Classical monocytes84.86 percentage of cellsStandard Deviation 8.92
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 4 - Classical monocytes83.27 percentage of cellsStandard Deviation 9.06
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 5 - Classical monocytes83.68 percentage of cellsStandard Deviation 10.25
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 6 - Classical monocytes85.39 percentage of cellsStandard Deviation 8.31
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 7 - Classical monocytes84.87 percentage of cellsStandard Deviation 8.45
ReduxiumInnate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium IntakeWeek 8 - Classical monocytes82.72 percentage of cellsStandard Deviation 10.86
Primary

Innate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium Intake

Blood tests of NK cell subsets utilising groups of labelled antibodies

Time frame: Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline

Population: healthy participants.

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeBaseline - CD16+CD56++0.94 percentage of cellsStandard Deviation 0.47
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 3 - CD16+CD56++1.09 percentage of cellsStandard Deviation 0.68
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeCD16++CD56- - Baseline0.89 percentage of cellsStandard Deviation 0.62
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 3 - CD16++CD56-0.91 percentage of cellsStandard Deviation 0.5
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 4 - CD16++CD56-0.99 percentage of cellsStandard Deviation 0.44
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 5 - CD16++CD56-0.83 percentage of cellsStandard Deviation 0.39
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 6 - CD16++CD56-1.02 percentage of cellsStandard Deviation 0.58
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 7 - CD16++CD56-1.24 percentage of cellsStandard Deviation 0.6
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 8 - CD16++CD56-1.34 percentage of cellsStandard Deviation 0.56
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeBaseline - CD16+CD56+67.89 percentage of cellsStandard Deviation 13.2
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 3 - CD16+CD56+66.63 percentage of cellsStandard Deviation 15.26
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 4 - CD16+CD56+66.31 percentage of cellsStandard Deviation 15.48
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 5 - CD16+CD56+67.07 percentage of cellsStandard Deviation 15.67
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 6 - CD16+CD56+69.92 percentage of cellsStandard Deviation 13.13
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 7 - CD16+CD56+69.86 percentage of cellsStandard Deviation 10.9
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 8 - CD16+CD56+69.04 percentage of cellsStandard Deviation 13.01
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 4 - CD16+CD56++0.96 percentage of cellsStandard Deviation 0.45
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 5 - CD16+CD56++0.90 percentage of cellsStandard Deviation 0.42
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 6 - CD16+CD56++1.08 percentage of cellsStandard Deviation 0.59
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 7 - CD16+CD56++1.06 percentage of cellsStandard Deviation 0.45
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 8 - CD16+CD56++1.23 percentage of cellsStandard Deviation 0.68
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeBaseline - CD16-CD56+2.05 percentage of cellsStandard Deviation 1.01
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 3 - CD16-CD56+1.78 percentage of cellsStandard Deviation 0.98
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 4 - CD16-CD56+1.68 percentage of cellsStandard Deviation 0.69
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 5 - CD16-CD56+1.68 percentage of cellsStandard Deviation 0.84
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 6 - CD16-CD56+1.61 percentage of cellsStandard Deviation 0.73
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 7 - CD16-CD56+1.66 percentage of cellsStandard Deviation 0.73
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 8 - CD16-CD56+1.56 percentage of cellsStandard Deviation 0.84
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeBaseline - CD16-CD56++2.98 percentage of cellsStandard Deviation 1.54
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 3 - CD16-CD56++2.90 percentage of cellsStandard Deviation 1.6
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 4 - CD16-CD56++2.66 percentage of cellsStandard Deviation 1.23
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 5 - CD16-CD56++2.61 percentage of cellsStandard Deviation 1.26
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 6 - CD16-CD56++2.84 percentage of cellsStandard Deviation 1.44
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 7 - CD16-CD56++2.67 percentage of cellsStandard Deviation 1.06
ReduxiumInnate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium IntakeWeek 8 - CD16-CD56++3.16 percentage of cellsStandard Deviation 1.79
Primary

Liver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium Intake

ALT blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium IntakeBaseline15.90 U/LStandard Deviation 7.66
ReduxiumLiver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium IntakeWeek 817.40 U/LStandard Deviation 9.45
Primary

Liver Panel (Albumin) After 2 Weeks of Reduxium Intake

Albumin blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Albumin) After 2 Weeks of Reduxium IntakeBaseline42.80 g/LStandard Deviation 3.37
ReduxiumLiver Panel (Albumin) After 2 Weeks of Reduxium IntakeWeek 842.95 g/LStandard Deviation 2.03
Primary

Liver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium Intake

ALP blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium IntakeBaseline62.90 U/LStandard Deviation 19.82
ReduxiumLiver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium IntakeWeek 859.90 U/LStandard Deviation 15.87
Primary

Liver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium Intake

AST blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium IntakeBaseline19.50 U/LStandard Deviation 3.35
ReduxiumLiver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium IntakeWeek 820.55 U/LStandard Deviation 4.15
Primary

Liver Panel (Bilirubin) After 2 Weeks of Reduxium Intake

Bilirubin blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Bilirubin) After 2 Weeks of Reduxium IntakeWeek 811.25 umol/LStandard Deviation 3.5
ReduxiumLiver Panel (Bilirubin) After 2 Weeks of Reduxium IntakeBaseline11.90 umol/LStandard Deviation 4.09
Primary

Liver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium Intake

LDH blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumLiver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium IntakeBaseline310.80 U/LStandard Deviation 43.87
ReduxiumLiver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium IntakeWeek 8377 U/LStandard Deviation 108.54
Primary

Renal Panel (Creatinine) After 2 Weeks of Reduxium Intake

Creatinine blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumRenal Panel (Creatinine) After 2 Weeks of Reduxium IntakeWeek 868.85 umol/LStandard Deviation 11.76
ReduxiumRenal Panel (Creatinine) After 2 Weeks of Reduxium IntakeBaseline69.05 umol/LStandard Deviation 12.09
Primary

Renal Panel (Potassium) After 2 Weeks of Reduxium Intake

Potassium blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumRenal Panel (Potassium) After 2 Weeks of Reduxium IntakeBaseline4.26 mmol/LStandard Deviation 0.49
ReduxiumRenal Panel (Potassium) After 2 Weeks of Reduxium IntakeWeek 84.54 mmol/LStandard Deviation 0.46
Primary

Renal Panel (Sodium) After 2 Weeks of Reduxium Intake

Sodium blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumRenal Panel (Sodium) After 2 Weeks of Reduxium IntakeBaseline139.55 mmol/LStandard Deviation 1.43
ReduxiumRenal Panel (Sodium) After 2 Weeks of Reduxium IntakeWeek 8139.40 mmol/LStandard Deviation 1.59
Primary

Renal Panel (Urea) After 2 Weeks of Reduxium Intake

Urea blood tests

Time frame: Baseline and week 8 post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
ReduxiumRenal Panel (Urea) After 2 Weeks of Reduxium IntakeBaseline4.20 mmol/LStandard Deviation 1.45
ReduxiumRenal Panel (Urea) After 2 Weeks of Reduxium IntakeWeek 84.04 mmol/LStandard Deviation 1.08
Secondary

Number of Adverse Events After Reduxium Intake

To analyse the safety and tolerability of Reduxium after 2 weeks of Reduxium intake, based on number of adverse events

Time frame: Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline

ArmMeasureValue (NUMBER)
ReduxiumNumber of Adverse Events After Reduxium Intake0 adverse events

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026